Evommune (Ticker: EVMN US) is a U.S. biotech company developing treatments for chronic inflammatory and immune-related conditions. Based in Palo Alto, California, the company plans to list on the NYSE on November 6, 2025, offering 9.4 million shares at $15–$17 each to raise up to $159.4 million. At the midpoint of the range, the IPO would value Evommune at around $543 million. Underwriters are Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor. Evommune’s lead drug candidate, EVO756, is an oral therapy currently in mid-stage trials for skin disorders such as chronic hives and eczema, with clinical results expected in the second half of next year. The company focuses on developing new medicines that address inflammation-driven diseases where current treatment options are limited.